Corcept Therapeutics: all 73 studies

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesRecruitingNCT07276373Phase 1/2
• Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT07259317Phase 2
• Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersRecruitingNCT06906341Phase 2
• Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerActive, not recruitingNCT05257408Phase 3Results posted
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)CompletedNCT04524403Phase 2Results posted
• Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT04329949Phase 3Results posted
• A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasCompletedNCT04308590Phase 3Results posted
• Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)TerminatedNCT03823703Phase 2Results posted
• A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic MedicationsCompletedNCT03818256Phase 2Results posted
• Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT03776812Phase 2Results posted
• A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeCompletedNCT03697109Phase 3Results posted
• Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerTerminatedNCT03437941Phase 1/2Results posted
• Study to Evaluate CORT125134 in Participants With Cushing's SyndromeCompletedNCT02804750Phase 2Results posted
• Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid TumorsCompletedNCT02762981Phase 1/2Results posted
• Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's SyndromeCompletedNCT01371565Phase 3Results posted
• An Extension Study of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00936741Phase 3Results posted
• A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male VolunteersCompletedNCT00698022Phase 1Results posted
• A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic FeaturesTerminatedNCT00637494Phase 3Results posted
• A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00569582Phase 3Results posted
• Evaluating the Pharmacokinetics and Safety of MiricorilantCompletedNCT07553663Phase 1
• Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult SubjectsCompletedNCT07240116Phase 1
• Evaluation of Miricorilant on Liver Fat in Patients With MASLDCompletedNCT06947304Phase 1
• Effects of Hepatic Impairment on the Pharmacokinetics of DazucorilantCompletedNCT06928779Phase 1
• Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)CompletedNCT06829537
• Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult ParticipantsCompletedNCT06495944Phase 1
• A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)CompletedNCT06108219Phase 2
• A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy SubjectsCompletedNCT06094790Phase 1
• A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy SubjectsCompletedNCT06094738Phase 1
• A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of RelacorilantCompletedNCT06094725Phase 1
• A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male SubjectsCompletedNCT06094712Phase 1
• Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)CompletedNCT05772169Phase 4
• Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of MiricorilantCompletedNCT05712265Phase 1
• Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of MiricorilantCompletedNCT05553470Phase 1
• Dazucorilant in Patients With Amyotrophic Lateral SclerosisActive, not recruitingNCT05407324Phase 2
• Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy ParticipantsCompletedNCT05347979Phase 1
• A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)CompletedNCT05320146
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)CompletedNCT05117489Phase 1
• Single and Multiple Ascending Dose Study of CORT125236 in Healthy ParticipantsCompletedNCT05003713Phase 1
• Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy ParticipantsCompletedNCT04994743Phase 1
• Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male ParticipantsCompletedNCT04990310Phase 1
• T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy VolunteersCompletedNCT04795479Phase 1
• Single and Multiple Ascending Dose Study of CORT125329 in Healthy ParticipantsCompletedNCT04672512Phase 1
• Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy ParticipantsCompletedNCT04672499Phase 1
• Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)CompletedNCT04373265Phase 1
• Single and Multiple Ascending Dose Study of CORT113176 in Healthy ParticipantsCompletedNCT04249323Phase 1
• Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male ParticipantsCompletedNCT03878264Phase 1
• Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male ParticipantsCompletedNCT03877952Phase 1
• The Effect of CORT118335 on Olanzapine-Induced Weight GainCompletedNCT03877562Phase 1
• Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeActive, not recruitingNCT03604198Phase 2
• A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule VariantsCompletedNCT03540836Phase 1
• Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its MetabolitesCompletedNCT03512548Phase 1
• CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)CompletedNCT03508635Phase 1
• Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450sCompletedNCT03457597Phase 1
• Relacorilant Food Effect Study in Healthy SubjectsCompletedNCT03442621Phase 1
• Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing SyndromeTerminatedNCT03379363
• CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)CompletedNCT03335956Phase 1
• First-in-human Study in Healthy SubjectsCompletedNCT03315338Phase 1
• Mifepristone Drug-Drug Interaction Study With CYP3A InhibitorCompletedNCT03259542Phase 1
• Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its MetabolitesCompletedNCT03258372Phase 1
• A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the BodyCompletedNCT03067376Phase 1
• Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After SurgeryCompletedNCT02922257
• Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's SyndromeCompletedNCT02663609
• Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid TumorsCompletedNCT02014337Phase 1
• Mifepristone in Children With Refractory Cushing's DiseaseWithdrawnNCT01925092Phase 3
• A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of HypercortisolemiaTerminatedNCT00796783
• A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy VolunteersCompletedNCT00752843Phase 1
• A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight GainCompletedNCT00455442Phase 2
• A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major DepressionCompletedNCT00208156Phase 3
• An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major DepressionCompletedNCT00146523Phase 3
• A United States Study of Corlux for Psychotic Symptoms in Psychotic Major DepressionCompletedNCT00130676Phase 3
• An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major DepressionCompletedNCT00128505Phase 3
• A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major DepressionCompletedNCT00128479Phase 3
• Mifepristone as Adjunctive Therapy in Alzheimer's DiseaseTerminatedNCT00105105Phase 2

← Corcept Therapeutics overview and focus areas